BR0010097A - Polinucleotìdeo isolado; célula hospedeira; processo para a produção de uma proteìna codificada pelo polinucleotìdeo; proteìna; composição; e; anticorpo - Google Patents

Polinucleotìdeo isolado; célula hospedeira; processo para a produção de uma proteìna codificada pelo polinucleotìdeo; proteìna; composição; e; anticorpo

Info

Publication number
BR0010097A
BR0010097A BR0010097-8A BR0010097A BR0010097A BR 0010097 A BR0010097 A BR 0010097A BR 0010097 A BR0010097 A BR 0010097A BR 0010097 A BR0010097 A BR 0010097A
Authority
BR
Brazil
Prior art keywords
protein
polynucleotide
antibody
composition
production
Prior art date
Application number
BR0010097-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Kenneth Jacobs
Lynette Fouser
Vikki Spaulding
Dejun Xuan
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22449618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0010097(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Inst filed Critical Genetics Inst
Publication of BR0010097A publication Critical patent/BR0010097A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
BR0010097-8A 1999-04-28 2000-04-28 Polinucleotìdeo isolado; célula hospedeira; processo para a produção de uma proteìna codificada pelo polinucleotìdeo; proteìna; composição; e; anticorpo BR0010097A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13147399P 1999-04-28 1999-04-28
PCT/US2000/011479 WO2000065027A2 (en) 1999-04-28 2000-04-28 Human gil-19/ae289 proteins and polynucleotides encoding same

Publications (1)

Publication Number Publication Date
BR0010097A true BR0010097A (pt) 2002-02-13

Family

ID=22449618

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010097-8A BR0010097A (pt) 1999-04-28 2000-04-28 Polinucleotìdeo isolado; célula hospedeira; processo para a produção de uma proteìna codificada pelo polinucleotìdeo; proteìna; composição; e; anticorpo

Country Status (14)

Country Link
EP (2) EP2357193B1 (enExample)
JP (2) JP4828703B2 (enExample)
AT (1) ATE377077T1 (enExample)
BR (1) BR0010097A (enExample)
CA (1) CA2367965C (enExample)
CY (1) CY1107138T1 (enExample)
DE (1) DE60036937T2 (enExample)
DK (1) DK1177312T3 (enExample)
ES (2) ES2295026T3 (enExample)
MX (1) MXPA01010883A (enExample)
NZ (1) NZ515678A (enExample)
PT (1) PT1177312E (enExample)
WO (1) WO2000065027A2 (enExample)
ZA (1) ZA200109270B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016611A2 (en) * 2000-08-24 2002-02-28 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6551799B2 (en) 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6274710B1 (en) 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
US6331613B1 (en) * 1998-10-26 2001-12-18 Ludwig Institue For Cancer Research Isolated nucleic acid molecules which encode T cell inducible factors (TIFS), the proteins encoded, and uses thereof
WO2000065027A2 (en) * 1999-04-28 2000-11-02 Genetics Institute, Inc. Human gil-19/ae289 proteins and polynucleotides encoding same
US6897292B2 (en) 1999-12-03 2005-05-24 Zymogenetics, Inc. Human cytokine receptor
US7226591B2 (en) 2000-05-22 2007-06-05 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
ATE459716T1 (de) * 1999-12-23 2010-03-15 Zymogenetics Inc Zytokin zcyt018
US20030170823A1 (en) 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
AU7303301A (en) * 2000-07-27 2002-02-13 Ludwig Inst Cancer Res Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof
WO2002012345A2 (en) 2000-08-08 2002-02-14 Zymogenetics, Inc. Soluble zcytor 11 cytokine receptors
US7094570B2 (en) 2003-03-11 2006-08-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US7268223B2 (en) 2000-09-22 2007-09-11 Wyeth Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
NZ527396A (en) * 2001-02-23 2007-12-21 Genetics Inst Llc Antibodies and fragments thereof for the binding of IL-22 and use therefore for treating inflammatory disorders
WO2002077174A2 (en) 2001-03-27 2002-10-03 Zymogenetics, Inc. Human cytokine receptor
US7033787B2 (en) 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
JP4504023B2 (ja) 2002-03-22 2010-07-14 ザイモジェネティクス インコーポレーティッド 抗ｉｌ−ｔｉｆ抗体および炎症において使用する方法
MXPA05010134A (es) 2003-03-24 2005-11-16 Zymogenetics Inc Anticuerpos anti-il-20, metodos y moleculas de enlace que se usan en la inflamacion.
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
US7537761B2 (en) 2004-10-22 2009-05-26 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
LT2816118T (lt) 2005-05-31 2018-12-10 The Regents Of The University Of Colorado, A Body Corporate Genų pristatymo būdai
EA035645B1 (ru) 2013-03-15 2020-07-21 Дженентек, Инк. ПОЛИПЕПТИДЫ IL-22, ХИМЕРНЫЕ БЕЛКИ IL-22 Fc И ИХ ПРИМЕНЕНИЕ

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5169939A (en) 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
US4798885A (en) 1986-02-07 1989-01-17 Genentech, Inc. Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5576184A (en) 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5126323A (en) 1989-11-16 1992-06-30 Genetics Institute, Inc. Homogeneous purified k-fgf and compositions containing the same
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5536637A (en) 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
US6664107B1 (en) 1993-05-26 2003-12-16 Ontario Cancer Institute, University Health Network CD45 disrupted nucleic acid
DK0716610T3 (da) 1993-08-26 2006-09-04 Genetics Inst Llc Humane knogle-morfogenetiske proteiner til anvendelse ved neural regenerering
DK0733109T3 (da) 1993-12-07 2006-07-03 Genetics Inst Llc BMP-12, BMP-13 og seneinducerende præparater dermed
US5679523A (en) 1995-11-16 1997-10-21 The Board Of Trustees Of The Leland Stanford Junior University Method for concurrent disruption of expression of multiple alleles of mammalian genes
US6331613B1 (en) * 1998-10-26 2001-12-18 Ludwig Institue For Cancer Research Isolated nucleic acid molecules which encode T cell inducible factors (TIFS), the proteins encoded, and uses thereof
US6274710B1 (en) * 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
WO2000065027A2 (en) * 1999-04-28 2000-11-02 Genetics Institute, Inc. Human gil-19/ae289 proteins and polynucleotides encoding same
WO2000073457A1 (en) * 1999-05-27 2000-12-07 Schering-Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
US20020187512A1 (en) * 2001-09-10 2002-12-12 Nagem Ronaldo Alves Pinto Crystal structure of human interleukin-22
TWI417301B (zh) * 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途

Also Published As

Publication number Publication date
PT1177312E (pt) 2008-01-22
WO2000065027A2 (en) 2000-11-02
DE60036937D1 (de) 2007-12-13
DE60036937T2 (de) 2008-08-07
EP1177312A4 (en) 2004-08-25
EP2357193B1 (en) 2015-11-04
EP2357193A1 (en) 2011-08-17
JP2011160804A (ja) 2011-08-25
ATE377077T1 (de) 2007-11-15
JP2003527078A (ja) 2003-09-16
ZA200109270B (en) 2002-11-13
EP1177312B1 (en) 2007-10-31
ES2295026T3 (es) 2008-04-16
HK1118576A1 (en) 2009-02-13
CA2367965C (en) 2015-12-01
WO2000065027A3 (en) 2001-04-05
NZ515678A (en) 2004-01-30
HK1041021A1 (en) 2002-06-28
JP4828703B2 (ja) 2011-11-30
CA2367965A1 (en) 2000-11-02
EP1177312A2 (en) 2002-02-06
MXPA01010883A (es) 2002-10-31
CY1107138T1 (el) 2012-10-24
ES2530857T3 (es) 2015-03-06
DK1177312T3 (da) 2008-02-25

Similar Documents

Publication Publication Date Title
BR0010097A (pt) Polinucleotìdeo isolado; célula hospedeira; processo para a produção de uma proteìna codificada pelo polinucleotìdeo; proteìna; composição; e; anticorpo
FR2566384B1 (fr) Perfectionnements aux techniques de production de microspheres en verre
ATE118821T1 (de) Nukleotidesequenzen, die ein protein mit ureareaktivität kodieren.
LV5288A3 (lv) Nukleinskabes fragments kurs kode cilveka proapolipoproteinu A-1
ATE484587T1 (de) Ldcam genannte moleküle
PT584452E (pt) Novas proteinas amiloides percursoras e metodos de utilizacao das mesmas
DK1129190T3 (da) Human TSLP DNA og polypeptider
DE3586189D1 (de) Menge und verfahren zur herstellung rekombinierter erzeugnisse in grosser ausbeute.
ES2063278T3 (es) Proteina morfogenetica de hueso.
AU6329694A (en) Recombinant expression vectors and purification methods for thermus thermophilus DNA polymerase
DE69930955D1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
BR8301918A (pt) Proteina,sequencia de dna,veiculo de expressao replicavel,microorganismo ou cultura celular,plasmideo,composicao,cultura de celulas,utilizacao de tal proteina,processo de expressao,processo para producao de um veiculo de expressao e processo para preparacao de uma proteina uroquinase
IL196900A0 (en) Autologous t-cell vaccines compositions
DK0688362T3 (da) Kloning og rekombinant fremstilling af vespidgiftenzymer, såsom phospholipase og hyaluronidase, og immunologiske terapier baseret derpå
FI952148L (fi) Geenitekninen menetelmä ja isäntä ksylitolin valmistamiseksi
DE68918673D1 (de) IgG-bindendes Protein H, kodierendes Gen dafür und Verfahren zu seiner Herstellung.
BR0316476A (pt) Composição e processo para tratar nefrite do lúpus
PT83968B (pt) Processo para melhoramento da expressao de proteina eucariotica, de preparacao de um plasmideo e plasmideo
WO2001090326A3 (en) Novel matrix metalloproteinases
AU2002222658A1 (en) Novel aggrecanase
ATE302214T1 (de) Enamel-matrix bezogene polypeptide
DK0422217T3 (da) Human, rekombinant, placental ribonucleaseinhibitor og fremgangsmåde til produktion
ES2056123T3 (es) Clonacion del gen que codifica la enzima isoamilasa y su empleo en la produccion de dicha enzima.
SE8403929D0 (sv) Recombinant dna molecule, transformed microorganisms and process for producing penicillin v amidase
ATE420962T1 (de) Rekombinante n-proteinase, deren herstellung, methoden und anwendungen

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 24, 25, 10 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]